Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND PROPOSED CANCELLATION OF THE SUPERVISORY COMMITTEE

The board (the "**Board**") of directors (the "**Directors**") of Suzhou Ribo Life Science Co., Ltd. (the "**Company**") is pleased to announce that, in order to (i) bring the articles of association of the Company (the "**Articles of Association**") in line with the latest regulatory requirements in relation to holding hybrid general meetings, providing electronic voting and the relevant amendments made to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); and (ii) in light of the latest regulatory requirements of the Company Law of the People's Republic of China, the Guidelines for Articles of Association of Listed Companies and Rules for General Meetings of Listed Companies issued by the China Securities Regulatory Commission and other laws and regulations which require, among other things, listed PRC companies to cancel the supervisory committee and further enhance the corporate governance, based on the actual situation of the Company, the Board has considered and approved, among others, the amendments (the "**Proposed Amendments**") to the Articles of Association, the procedural rules of the general meeting of the Company and the procedural rules of the Board. At the same time, according to the aforesaid laws and regulations and regulatory requirements, the Company proposes to cancel the supervisory committee of the Company (the "**Supervisory Committee**"), with the relevant powers of the Supervisory Committee to be exercised by the audit committee of the Board.

The Proposed Amendments and the proposed cancellation of the Supervisory Committee are subject to the consideration and approval by the Shareholders as special resolutions at the upcoming annual general meeting of the Company. With effect from the date on which the amended Articles of Association come into effect, the current supervisors of the Company shall be relieved of their duties, and the rules of procedure for the Supervisory Committee shall be repealed accordingly. Prior to the approval of the amendments to the Articles of Association by the shareholders of the Company (the "**Shareholders**") at the upcoming annual general meeting of the Company, the Supervisory Committee shall continue to perform due diligence in their duties to safeguard the interests of the Company and all Shareholders. A circular containing, among others, details of the resolutions on the Proposed Amendments and the proposed cancellation of the Supervisory Committee together with the notice of the annual general meeting will be published on the websites of HKEXnews (https://www.hkexnews.hk) and the Company (https://www.ribolia.com) and will be despatched to Shareholders (if applicable) in accordance with the requirements of the Listing Rules in due course.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, March 25, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.